Introduction
AML, tumors, tumor
TUMOR, ACUTE MYELOID LEUKEMIA, AML, REMISSION, TUMORS, HEMATOLOGICAL MALIGNANCY
Acute myeloid leukemia (AML) is a hematological malignancy characterized by an autonomous growth of myeloid blast cells that cannot differentiate or further develop into mature white blood cells. Moreover, it has a diverse clinical presentation [While AML is now treatable and curable, the long-term survival rate after complete remission (CR) with chemotherapy remains low at about 40%, and the relapse rate remains high [Intermolecular interactions with murine double minute 2 (MDM2) frequently inhibit the tumor suppressor protein p53 activity in human tumors harboring wild-type p53. MDM2 promotes p53 nuclear export or p53 degradation via the ubiquitin–proteasome pathway, which maintains low p53 activity levels [Milademetan (DS-3032, RAIN-32) is an orally administered small-molecule MDM2 inhibitor, and in vitro studies show that it inhibits the MDM2–p53 interaction and has a p53 status-dependent antitumor effect [